Patterns of immune-related adverse events (irAEs) in adolescent and young adult (AYA) patients with melanoma receiving immune checkpoint inhibitors (ICIs).

• DOI: 10.1200/jco.2024.42.16_suppl.12117
• Publication Date: 2024-06-13T18:32:07Z
• Authors: Jiasen He; Ida John; Faraz Afridi; Mianen Sun; Yinghong Wang; Michael Roth; Jennifer Leigh Mc...
• Keywords: Immune checkpoint

12117 Background: ICIs are increasingly used in AYAs with cancer, however, limited data exists on the frequency and pattern of irAEs this population ability to rechallenge after irAEs. Methods: This retrospective study analyzed aged 15-39 melanoma who received treatment at MD Anderson Cancer Center from 2013 2023. Treatment cessation was defined as switching therapies or pausing original for over 3 months, resuming immunotherapy post-cessation. Results: A total 136 pts were included, 80 male (59%), median age 33 years (range, years) upon initial ICI exposure. The majority had non-acral cutaneous (107, 79%) 83 (63%) a BRAF V600E/R/K alteration. Ninety-three percent patients stage III/IV cancer initiation. Targeted therapy 20 (15%) prior starting 16 (12%) concurrently. Combination utilized 43% cases, while monotherapy 57%. intent adjuvant 51% palliative 37% neoadjuvant 12%. incidence any-grade grade 1st line 60% 21% full cohort (with combination CTLA-4/PD-1 blockers 70% 33%; PD-1 50% 9%, respectively). Forty-eight multi-system (35%) 23 III/IV. Thirty-two (24%) their stopped due hepatitis (31%, 10/32) colitis (28%, 9/32) being most common causes. Eighteen (13%) irAE-related hospitalizations. Specific listed table. Seventy-two (53%) rechallenged ICIs. Of these, 51 previous among 71% recurrent Seventy-six (36/51) experienced again 33% (17/51) having same Twenty-six (13/51) Conclusions: In treated ICIs, irAE is one major reasons interruption. appears somewhat lower than rates previously reported registrational trials, though should be interpreted caution given nature current study. Patients have higher risk new rechallenge, low without serious negative outcome. [Table: see text]